Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Drugs Used in Lower Respiratory Disorders: Overview

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

Asthma-IV: Diagnostic and Management

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

Asthma I: Introduction

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...

Asthma-II: Pathophysiology and Classification

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Peanut oral immunotherapy at a single academic medical center using a volume-based approach with store-purchased peanut products.

The journal of allergy and clinical immunology. Global·2026

Same author

American Society for Gastrointestinal Endoscopy consensus recommendations on the endoscopic management of eosinophilic esophagitis-part 2: disease assessment, monitoring, and pediatric considerations.

Gastrointestinal endoscopy·2026

Same author

One-food versus 4-food elimination diet for pediatric eosinophilic esophagitis: A multisite randomized trial.

The Journal of allergy and clinical immunology·2024

Same author

T<sub>H</sub>2 cell compensatory effect following benralizumab treatment for eosinophilic gastritis.

The Journal of allergy and clinical immunology·2024

Same author

Losartan Treatment Reduces Esophageal Eosinophilic Inflammation in a Subset of Eosinophilic Esophagitis.

The journal of allergy and clinical immunology. In practice·2024

Same author

Mast cell activation syndrome: Current understanding and research needs.

The Journal of allergy and clinical immunology·2024

Search research articles

Related Experiment Video

Updated: May 30, 2026

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis

Published on: May 10, 2024

Mepolizumab in eosinophilic disorders.

J Pablo Abonia¹, Philip E Putnam

¹Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, ML2010, Cincinnati, OH 45229-3039, USA.

Expert Review of Clinical Immunology

|July 28, 2011

Summary

Mepolizumab is a biologic agent targeting IL-5, showing potential therapeutic benefits in eosinophil-related disorders beyond asthma. Further research evaluates its impact across various conditions.

More Related Videos

Methodology for Sputum Induction and Laboratory Processing

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

Related Experiment Videos

Last Updated: May 30, 2026

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis

Published on: May 10, 2024

Methodology for Sputum Induction and Laboratory Processing

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

Area of Science:

Immunology
Pharmacology
Respiratory Medicine

Background:

Mepolizumab is a humanized monoclonal antibody targeting interleukin-5 (IL-5).
It is approved for treating asthma by inhibiting IL-5 signaling.
Its efficacy in other eosinophil-related disorders is under investigation.

Purpose of the Study:

To evaluate preclinical and clinical studies on mepolizumab.
To assess the impact of mepolizumab in various eosinophilic disorders.

Main Methods:

Review of existing preclinical data.
Analysis of published clinical trial results.
Assessment of mepolizumab's mechanism of action.

Main Results:

Mepolizumab targets the IL-5 pathway, crucial in eosinophil proliferation and activation.
Studies suggest potential therapeutic benefits in conditions like hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis.
Evidence indicates a role in reducing eosinophil counts and associated inflammation.

Conclusions:

Mepolizumab demonstrates potential as a treatment for eosinophil-driven diseases.
Further clinical investigation is warranted to establish its efficacy and safety profile in diverse eosinophilic disorders.
The drug's targeted approach offers a promising therapeutic strategy.